LIFE SCIENCES & HEALTH
Early in 2011, the Dutch Ministry of EL&I
published a new industrial policy in which nine topsectors were nominated. Life Science and Health is one of these. In response to this industrial policy letter from EL&I, a so-called topteam LS&H, consisting of entrepreneurs, top-scientists and government, has develop a vision for the future (
) and indicated what steps must be taken to secure competiveness and sustained innovation efforts of this sector at the global level.
Subsequently this topteam was asked to further elaborate their proposals. These proposals must clearly describe of the scientific excellence of the research and innovation efforts in the Netherlands, and also the potential for creating economic and societal value. This activity is now coordinated by the newly established Regiegroep LS&H
, supported by various Taskforces and in consultation with stakeholders.
BMM actively pursues collaboration with partners in the life sciences and health sector, in particular with CTMM
and TI Pharma
, and with the public at large. The Dutch life sciences and health sector is according to a kind of pipeline structure. BMM, together with NIRM
fill up the regenerative medicine pipeline. Within this so called ‘knowledge’ pipeline, each initiative takes up its own position. NIRM is positioned at the beginning of the pipeline, at the build phase. BMM aims at bundling of knowledge and technology at the bundle phase. TERM is positioned at the end of the pipeline aiming at translating knowledge into clinical application and economic value creation. This is the benefit phase.